{"id":2157,"date":"2026-06-08T15:00:00","date_gmt":"2026-06-08T18:00:00","guid":{"rendered":"https:\/\/sevenresiduosaude.com.br\/blog\/?p=2157"},"modified":"2026-06-08T15:00:00","modified_gmt":"2026-06-08T18:00:00","slug":"rss-hematologia-clinica-anemia-vte-hemofilia-talassemia-coagulopatia-warfarina-doac-emicizumab","status":"publish","type":"post","link":"https:\/\/sevenresiduosaude.com.br\/blog\/rss-hematologia-clinica-anemia-vte-hemofilia-talassemia-coagulopatia-warfarina-doac-emicizumab\/","title":{"rendered":"RSS hematologia cl\u00ednica: anemia, VTE, hemofilia"},"content":{"rendered":"

A regula\u00e7\u00e3o brasileira de RSS \u00e9 frequentemente desafiada por gestores de centros de hematologia cl\u00ednica n\u00e3o-oncol\u00f3gica. Em 2026, h\u00e1 uma demanda crescente de hospitais com unidade hemato cl\u00ednica \u2014 anemias<\/strong> ferropriva (ferro IV Venofer + Ferinject + Monofer R$ 800-2k\/dose) + megalobl\u00e1stica B12+folato + siderobl\u00e1stica + apl\u00e1stica idiop\u00e1tica + falciforme S\/SC\/SS, doen\u00e7a falciforme HbSS\/SC<\/strong> com hidroxiureia Hydrea + crizanlizumab Adakveo + voxelotor Oxbryta + L-glutamina Endari + transfus\u00e3o chronica + apheresis HbSS, VTE venous thromboembolism<\/strong> TVP + TEP + DVT + PE com warfarina Marevan\/Coumadin INR-guided + DOAC direct oral anticoagulants apixaban Eliquis + rivaroxaban Xarelto + dabigatran Pradaxa + edoxaban Lixiana, hemofilia A FVIII<\/strong> + hemofilia B FIX<\/strong> com fator VIII recombinante Advate + Adynovate + Kovaltry + Kogenate + Eloctate + Esperoct + Adynovi long-acting + emicizumab Hemlibra<\/strong> Roche bispecific Ab + fitusiran Qfitlia<\/strong> RNAi siRNA + gene therapy Roctavian valoctocogene roxaparvovec<\/strong> BioMarin + Hemgenix etranacogene dezaparvovec<\/strong> CSL Behring R$ 14-25M dose \u00fanica, PTI P\u00farpura Trombocitop\u00eanica Imune ITP<\/strong> com prednisona + IVIG + rituximab + romiplostim Nplate + eltrombopag Promacta + fostamatinib Tavalisse, PTT P\u00farpura Trombocitop\u00eanica Tromb\u00f3tica<\/strong> com plasma fresco congelado + caplacizumab Cablivi + rituximab + apheresis tromb\u00f3tica di\u00e1ria, talassemia \u03b2-major<\/strong> com transfus\u00e3o cr\u00f4nica + deferasirox Exjade + deferiprona Ferriprox + deferoxamina Desferal quelante ferro + luspatercept Reblozyl + zynteglo betibeglogene autotemcel gene therapy R$ 14-25M. A consequ\u00eancia \u00e9 a urg\u00eancia de PGRSS dedicado para hemato cl\u00ednica<\/strong> \u2014 captura de fator VIII\/IX recombinante<\/strong> Advate Baxalta+Adynovate+Kovaltry Bayer+Kogenate+Eloctate Bioverativ+Esperoct Novo Nordisk Lista C5 R$ 4-12k\/dose \u00d7 100-300 doses\/paciente\/ano = R$ 400k-3.6M\/ano por hemof\u00edlico + cofre + cadeia fria 2-8\u00b0C, emicizumab Hemlibra<\/strong> Roche bispecific Ab Lista C5 R$ 8-15k\/dose mensal\/quinzenal + fitusiran Qfitlia<\/strong> Sanofi RNAi monthly SC, gene therapy Roctavian + Hemgenix + Zynteglo<\/strong> CSL Behring\/BioMarin\/Bluebird Bio dose \u00fanica R$ 14-25M com REMS espec\u00edfico + monitoriza\u00e7\u00e3o lifelong + livro RBI lifelong, DOAC<\/strong> Eliquis BMS+Xarelto Bayer+Pradaxa BI+Lixiana Daiichi Sankyo Lista B oral \u00d7 500-2.000 pacientes VTE = R$ 4-30M\/ano em DOAC + farm\u00e1cia cl\u00ednica, bolsa hemoderivado<\/strong> PRBC + plaquetas + plasma fresco congelado + crioprecipitado + apheresis kit Spectra Optia + Amicus Fenwal R$ 800-2k\/sess\u00e3o + cadeia fria 4\u00b0C\/-30\u00b0C\/22\u00b0C, hidroxiureia Hydrea<\/strong> + crizanlizumab Adakveo<\/strong> Novartis anti-P-selectina + voxelotor Oxbryta<\/strong> Pfizer + L-glutamina Endari<\/strong> + luspatercept Reblozyl<\/strong> Acceleron Lista C5, deferasirox Exjade<\/strong> + deferiprona Ferriprox<\/strong> + deferoxamina Desferal<\/strong> Lista C5 quelantes ferro talassemia. A realidade \u00e9 que hemato cl\u00ednica produz RSS de alt\u00edssimo valor terap\u00eautico. PGRSS de hemato cl\u00ednica \u00e9 cadeia integrada<\/strong> \u2014 come\u00e7a no diagn\u00f3stico<\/strong> (CBC + reticul\u00f3cito + ferro + ferritina + B12 + eletroforese Hb + coagulograma + FVIII\/IX), passa pela terapia<\/strong> (transfus\u00e3o + fator + emicizumab + DOAC + gene therapy) e termina no acompanhamento<\/strong> (INR + monitor lifelong gene therapy + AAV neutralizing antibody). O conjunto soma R$ 35.000-78.000\/m\u00eas<\/strong> que muitos gestores subestimam.<\/p>\n

Para o gestor que opera ou planeja unidade hemato cl\u00ednica, \u00e9 fundamental considerar a complexidade desde o in\u00edcio.<\/p>\n

Os procedimentos hematologia cl\u00ednica e os RSS espec\u00edficos<\/h2>\n

Em uma opera\u00e7\u00e3o de qualquer porte, a cadeia gera RSS espec\u00edficos.<\/p>\n\n\n\n\n\n\n\n\n\n
Cen\u00e1rio<\/th>\nInsumo cr\u00edtico<\/th>\nMedica\u00e7\u00e3o<\/th>\nRisco RSS<\/th>\n<\/tr>\n<\/thead>\n
Anemia falciforme HbSS<\/td>\nApheresis Spectra Optia<\/td>\nAdakveo+Oxbryta+Endari Lista C5<\/td>\nA4 + B Lista C5<\/td>\n<\/tr>\n
VTE TVP+TEP<\/td>\nBolsa anticoagula\u00e7\u00e3o<\/td>\nDOAC Eliquis\/Xarelto\/Pradaxa Lista B<\/td>\nA4 + B Lista B<\/td>\n<\/tr>\n
Hemofilia A FVIII<\/td>\nFrasco recombinante<\/td>\nFVIII Advate+Adynovate Lista C5<\/td>\nA4 + B + cadeia fria<\/td>\n<\/tr>\n
Gene therapy Roctavian<\/td>\nVetor AAV5 R$ 14-25M<\/td>\nValoctocogene roxaparvovec<\/td>\nA4 + B + biol\u00f3gico GMO<\/td>\n<\/tr>\n
Talassemia ferro overload<\/td>\nComprimido oral quelante<\/td>\nDeferasirox Exjade+Reblozyl C5<\/td>\nA4 + B Lista C5<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A soma t\u00edpica \u00e9 entre R$ 35.000-78.000\/m\u00eas<\/strong> em PGRSS dedicado de hemato cl\u00ednica vs R$ 12.000-25.000<\/strong> em PGRSS gen\u00e9rico subdimensionado.<\/p>\n

A hemofilia + fator + emicizumab + gene therapy: o procedimento de alt\u00edssimo investimento<\/h2>\n

A primeira camada do desafio \u00e9 a hemofilia. Padr\u00e3o setorial inclui (a) fator VIII recombinante<\/strong> Advate Baxalta + Adynovate Takeda + Kovaltry Bayer + Kogenate + Eloctate Bioverativ + Esperoct Novo Nordisk + Adynovi long-acting + fator IX<\/strong> AlphaNine + Mononine + BeneFIX + Idelvion + Rebinyn Lista C5 R$ 4-12k\/dose \u00d7 100-300 doses\/ano por paciente; (b) emicizumab Hemlibra<\/strong> Roche anti-FIXa\/FX bispecific Ab Lista C5 R$ 8-15k\/dose mensal\/quinzenal SC profilaxia; (c) fitusiran Qfitlia<\/strong> Sanofi RNAi monthly SC para AT antithrombin reduction; (d) gene therapy Roctavian valoctocogene roxaparvovec<\/strong> BioMarin AAV5-FVIII + Hemgenix etranacogene dezaparvovec<\/strong> CSL Behring AAV5-FIX dose \u00fanica R$ 14-25M; (e) livro RBI gene therapy<\/strong> com REMS + reten\u00e7\u00e3o lifelong + monitoriza\u00e7\u00e3o AAV neutralizing antibody.<\/p>\n

Hospital com 30-100 hemof\u00edlicos \u00d7 R$ 1-3M\/ano em fator\/emicizumab\/gene therapy = R$ 30M-300M\/ano em hemofilia + cofre Lista C5. Como discutimos no post sobre PGRSS de hemato onc<\/a>, Lista C5 + gene therapy \u00e9 estruturante.<\/p>\n

A VTE + DOAC + warfarina + farm\u00e1cia cl\u00ednica: o est\u00e1gio de alt\u00edssimo volume<\/h2>\n

A segunda camada \u00e9 o VTE. Padr\u00e3o setorial inclui (a) DOAC direct oral anticoagulants<\/strong> apixaban Eliquis BMS + rivaroxaban Xarelto Bayer + dabigatran Pradaxa BI + edoxaban Lixiana Daiichi Sankyo Lista B; (b) warfarina Marevan\/Coumadin<\/strong> INR-guided 2-3 + cl\u00ednica de anticoagula\u00e7\u00e3o + ponto de cuidado POC INR; (c) HBPM heparina baixo peso molecular<\/strong> enoxaparina Clexane + dalteparina Fragmin + nadroparina Fraxiparina Lista B; (d) ant\u00eddoto<\/strong> andexanet alfa Andexxa para anti-Xa + idarucizumab Praxbind para dabigatran R$ 25-65k\/dose; (e) tromb\u00f3lise<\/strong> alteplase rt-PA Actilyse + tenecteplase Metalyse para TEP massivo.<\/p>\n

Hospital com 500-2.000 VTEs\/ano \u00d7 DOAC R$ 200-400\/m\u00eas \u00d7 6-12 meses = R$ 600k-9.6M\/ano em DOAC + farm\u00e1cia cl\u00ednica.<\/p>\n

A doen\u00e7a falciforme + talassemia + apheresis: o est\u00e1gio cr\u00f4nico<\/h2>\n

A terceira camada \u00e9 o cr\u00f4nico. Padr\u00e3o setorial inclui (a) doen\u00e7a falciforme HbSS\/SC<\/strong> com hidroxiureia Hydrea + crizanlizumab Adakveo<\/strong> Novartis anti-P-selectina mensal + voxelotor Oxbryta<\/strong> Pfizer HbS polymerization inhibitor + L-glutamina Endari<\/strong> Lista C5 R$ 8-25k\/m\u00eas; (b) transfus\u00e3o cr\u00f4nica + apheresis HbSS<\/strong> Spectra Optia red cell exchange RCE 4-6 sem; (c) talassemia \u03b2-major<\/strong> com transfus\u00e3o cr\u00f4nica + deferasirox Exjade<\/strong> + deferiprona Ferriprox<\/strong> + deferoxamina Desferal<\/strong> Lista C5 quelantes ferro; (d) luspatercept Reblozyl<\/strong> Acceleron + zynteglo betibeglogene autotemcel<\/strong> Bluebird Bio gene therapy R$ 14-25M dose \u00fanica; (e) TMO alog\u00eanico<\/strong> REDOME + REREME + criopreserva\u00e7\u00e3o CryoStor + N2 -196\u00b0C.<\/p>\n

Hospital com 100-300 falciformes + 50-150 talassemias \u00d7 R$ 15-30k\/m\u00eas \u00d7 12 meses = R$ 18-108M\/ano em hemoglobinopatia + Lista C5.<\/p>\n

Tr\u00eas perfis de PGRSS para hemato cl\u00ednica<\/h2>\n

PGRSS gen\u00e9rico subdimensionado.<\/strong> Sem cobertura espec\u00edfica para fator + emicizumab + gene therapy + DOAC + Lista C5 hemoglobinopatia. Custo mensal R$ 12.000-25.000<\/strong>, efic\u00e1cia limitada.<\/p>\n

PGRSS dedicado intermedi\u00e1rio.<\/strong> Cobertura para anemia + VTE, sem hemofilia gene therapy + apheresis HbSS. Custo mensal R$ 25.000-50.000<\/strong>, efic\u00e1cia 100-200%.<\/p>\n

PGRSS dedicado completo hemato cl\u00ednica.<\/strong> Anemia + falciforme + VTE + hemofilia + talassemia + gene therapy + integra\u00e7\u00e3o com PGRSS de hemato onc<\/a>. Custo mensal R$ 50.000-78.000<\/strong>, ROI 250-500%.<\/p>\n

Os tr\u00eas erros que aparecem em PGRSS hemato cl\u00ednica subdimensionado<\/h2>\n

O primeiro \u00e9 o subdimensionamento de gene therapy lifelong<\/strong>. Roctavian\/Hemgenix\/Zynteglo R$ 14-25M dose \u00fanica + REMS lifelong + livro RBI espec\u00edfico.<\/p>\n

O segundo \u00e9 a aus\u00eancia de Lista C5 fator + emicizumab + Adakveo<\/strong>. R$ 4-15k\/dose \u00d7 100-300 doses\/ano com cofre + cadeia fria + livro 344.<\/p>\n

O terceiro \u00e9 a descarte de bolsa apheresis Spectra Optia como Grupo D<\/strong>. Apheresis Spectra Optia + Amicus Fenwal R$ 800-2k\/sess\u00e3o \u00e9 A1 + RAEE.<\/p>\n

A regula\u00e7\u00e3o de PGRSS no Brasil est\u00e1 em fase de moderniza\u00e7\u00e3o t\u00e9cnica acelerada com hemato cl\u00ednica como prioridade. As institui\u00e7\u00f5es que estruturam PGRSS dedicado desde o in\u00edcio \u2014 alinhadas com calend\u00e1rio 2026 de compliance<\/a> \u2014 atravessam o crescimento sem solavanco. Para gestores que precisam alinhar com gest\u00e3o paralela industrial, o portal Seven Res\u00edduos sobre servi\u00e7os completos<\/a> traz a perspectiva integrada. A ABHH Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular<\/a> \u00e9 refer\u00eancia t\u00e9cnica.<\/p>\n

Solicite cota\u00e7\u00e3o PGRSS de hematologia cl\u00ednica<\/a><\/strong> \u2014 cap\u00edtulo dedicado a anemia falciforme Adakveo+Oxbryta+Endari+hidroxiureia, VTE DOAC Eliquis+Xarelto+Pradaxa+Lixiana, hemofilia FVIII Advate+emicizumab Hemlibra+gene therapy Roctavian\/Hemgenix, talassemia deferasirox Exjade+luspatercept Reblozyl+Zynteglo gene therapy, PTI\/PTT romiplostim Nplate+caplacizumab Cablivi.<\/p>\n","protected":false},"excerpt":{"rendered":"

Hematologia cl\u00ednica gera RSS espec\u00edfico \u2014 anemia, VTE, hemofilia, talassemia. PGRSS dedicado.<\/p>\n","protected":false},"author":3,"featured_media":2156,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[2987,2986,2989,2988],"class_list":["post-2157","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-compliance-legislacao","tag-anemia","tag-hematologia-clinica","tag-hemofilia","tag-vte"],"_links":{"self":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2157","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/comments?post=2157"}],"version-history":[{"count":1,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2157\/revisions"}],"predecessor-version":[{"id":4303,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2157\/revisions\/4303"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media\/2156"}],"wp:attachment":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media?parent=2157"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/categories?post=2157"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/tags?post=2157"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}